The group’s principle activities include developing and commercializing cardiovascular therapeutics for treating medical conditions. The group’s products include Saratin and cardiovascular risk reduction products. The group operates from United States.
Executive Information
Name
Title
Email
John Parrish
Dir., CEO, Pres.
N/A
Alison Pilgrim
Chief Medical Officer, VP - Clinical Research, Regulatory Affairs
